Gilead Sciences Inc (GILD)

[dhbuzz]

Oral version of Gilead's remdesivir demonstrates promising preclinical results
Sep. 15, 2021 8:29 AM ETGilead Sciences, Inc. (GILD)Merck & Co., Inc. (MRK)By: Jonathan M Block, SA News Editor5 Comments
Pack of Remdesivir pills
AlexSava/E+ via Getty Images
An oral version of a prodrug of the parental nucleoside of Gilead's (NASDAQ:GILD) antiviral remdesivir showed promise in a preclinical study.
The prodrug, GS-621763, demonstrated antiviral activity both in lung cell lines and in mice infected with SARS-CoV-2, according to results published in bioRxiv. The results have yet to be peer reviewed.
GS-621763 was also compared against molnupiravir, Merck's (NYSE:MRK) oral antiviral that the company expects will receive Emergency Use Authorization for COVID-19 by the end of the year, and both drugs had similar efficacy.
In the U.S., Veklury (remdesivir) is indicated for adults and children 12 years of age and older for the treatment of COVID-19 requiring hospitalization.
Now Read: Gilead: Fundamentals With A Booster Shot